On March 26, 2025, the FDA approved Fresenius Kabi’s denosumab biosimilars, CONEXXENCE® (denosumab-bnht) and BOMYNTRA® (denosumab-bnht), referencing Amgen’s PROLIA® and XGEVA®, respectively. These approvals make Fresenius the fourth company to receive FDA approval for a pair of denosumab biosimilars, joining Celltrion, Samsung, and Sandoz.
Denosumab is a RANK ligand (RANKL) inhibitor that is used to treat bone loss. The FDA approved CONEXXENCE ® for use in various adult patient populations at high risk for fractures, including those with osteoporosis, individuals undergoing certain cancer treatments that affect bone density, and patients receiving long-term glucocorticoid therapy. The FDA approved BOMYNTRA ® to treat hypercalcemia of malignancy that is refractory to bisphosphonate therapy and giant cell tumor of bone in adults and skeletally mature adolescents, and to prevent skeletal-related events in adult patients with multiple myeloma and bone metastases from solid tumors.
On the same day, Fresenius also announced that they have “reached a global settlement with Amgen for [their] denosumab biosimilar candidates.” This announcement follows our previous report that Amgen and Fresenius settled their BPCIA case on March 7, 2025.
The post FDA Approves Fresenius’s Denosumab Biosimilars appeared first on Big Molecule Watch.